Senseonics Holdings, Inc.

Senseonics makes the Eversense 365 continuous glucose monitor — the only long-term implantable CGM on the market, positioned as a differentiated alternative to Dexcom and Abbott's disposable devices for patients who value the longer wear time and reduced site-change burden.

• The Q2 revenue trajectory is a genuine inflection: revenue of $14.5M grew 118% YoY, EPS of -$0.63 was a slight miss vs -$0.61 but the top-line pace is what matters at this stage — for a business with $62M FY26 revenue consensus (implying ~$15M/quarter run-rate), Q2 shows the Eversense 365 launch is on track to hit or beat that target.
• The economics support scaling if margins hold: 59% gross margin at Q2 revenue levels is above what most CGM peers achieved at similar scale, and the Ascensia commercial partnership is providing the distribution muscle — the -224% operating margin looks alarming but is a scale problem, not a unit-economics problem.
• The tape confirms the mechanical improvement: shares sit at the 43rd percentile of the 52-week range, +30% vs the 50-day and +20% vs the 200-day, with 30-day volume running 1.22x — that's the tape shape of a small-cap turnaround where the market is catching up to a revenue re-acceleration ahead of profitability.

What extends the accelerating trajectory is the Nov 4 print confirming Q2 revenue pace and any specific commentary on Eversense 365 unit-shipment velocity plus international expansion; what interrupts it is a Dexcom or Abbott competitive move (a longer-wear disposable product) or a distribution stumble at Ascensia that slows the launch cadence.